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A B S T R A C T
Objectives: there are very few value frameworks (VFs) to assess health technologies that are focused on diagnostic tests; they
usually do not reflect a multistakeholder process; and they are all developed in high-income countries. Our project performed
a targeted systematic review, with the objective of proposing an evidence-based, up-to-date VF informed by a multinational
multistakeholder group working in the health technology assessment (HTA) space.
Methods: (1) A targeted systematic review, with the aim to identify existing VFs and their dimensions; and (2) generation a VF
proposal through a mixed-methods, qualitative-quantitative approach.
Results: From 73 citations identified, 20 met our inclusion criteria and served to provide the initial list of dimensions for our
VF. An initial list of criteria and subcriteria for a preliminary VF was proposed. After a full-day deliberative face-to-face
meeting with 30 relevant stakeholders from seven Latin American countries and the United Kingdom, the final VF was
defined, consisting of 15 criteria: five “essential or core,” six highly relevant, three moderately relevant, and one of low
relevance. Barriers and facilitators of value assessment of diagnostic technologies were also discussed.
Conclusions: We propose a VF oriented to diagnostic technologies based on a targeted systematic review and a participatory
process with key HTA stakeholders. It is the first to be produced in a lower and middle income setting but can also be
potentially useful in other contexts aimed to assist decision-making processes with these particularly complex health
technologies.
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Introduction
Diagnostic tests are a heterogeneous group of technologies
with significant complexity in several relevant aspects or di-
mensions that decision makers need to assess when integrating
their value.1,2 Among the different aspects to bear in mind when
assessing a diagnostic technology, some of the most important are
not only the diagnostic ability of the test or the process it entails,
but also its eventual ability to improve clinical decision making,
the choice of treatments, and the final patient relevant outcomes.
In this way, the test is usually considered within the entire patient
care process or pathway. It is in this context that the value of a
diagnostic test or diagnostic technology is reflected, through the
value of the information generated for multiple aspects related to
health and healthcare, such as the selection of a treatment, the
determination of a state of health, the prognostic information for
the patient or their offspring, the monitoring of a treatment, or the
personalization of a therapeutic scheme.3-5
In a context where decision makers in health systems tradi-
tionally focus on drugs and prioritize dimensions such as
efficacy, safety, and costs when evaluating a health technology to
be covered or financed, diagnostic technologies impose signifi-
cant challenges for assessment.6 They may be assessed in a
rather partial or suboptimal way when using the same assess-
ment criteria as drugs, with the consequent misjudgment of
their value (either in a positive or a negative way) when deciding
about their incorporation in a benefits package or healthcare
system.7-10
The coronavirus disease 2019 (COVID-19) outbreak challenges
health systems from the first line of assistance to the ones that
have to make strategic and coverage decisions.11 The adoption of
testing strategies implies the consideration of a broad spectrum of
factors, many of which involve a high degree of uncertainty. In this
particularly pressing example, a framework that makes visible the
factors that decision makers have to consider in the assessment of
a diagnostic technology can serve as a compass in the decision-
making process. When writing this article, there is still not a
specific treatment or vaccine, but there are several diagnostic
tests.12-14 Which should each health system adopt? To whom?
These are not easy questions to answer.
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Value frameworks (VFs) attempt to communicate in a trans-
parent and explicit way the important dimensions for decision
making, and they usually reflect the preferences or values of the
different actors involved in their construction and use. They
basically define what dimensions are the most important—and
thus which are less so—when judging the value of a health
intervention.15,16
There are numerous examples of “generic” VFs used for the
evaluation of a wide range of health technologies, but most are
designed for or apply more straightforwardly to drugs or other
therapeutic technologies. Some have been internationally devel-
oped, although there are also regional value frameworks or some
developed in a particular country, or even oriented to decision
making under specific health conditions (ie, oncology) or specific
settings (ie, patient-centered decisions).17-22 A specific VF to
evaluate a diagnostic technology, on the other hand, tries to focus
on this particular type of technology and to reflect the value di-
mensions of the tests within the entire patient care pathway.
There is no study to our knowledge that has (1) synthesized
value frameworks that target diagnostic technologies and (2) used
this information to derive a value framework with the participa-
tion of a broad audience of key stakeholders in a deliberative and
integrated way, particularly in Latin America. Thus, our project
performed a targeted systematic review, with the objective of
proposing an evidence-based, up-to-date VF informed by a broad
group of stakeholders working in the health technology assess-
ment (HTA) space, which could help to guide and inform
evidence-based decision making.
Methods
This project was conducted to delineate a value framework for
diagnostic technologies useful especially in the context of the HTA
space. It was led by a team of researchers from the Institute for
Clinical Effectiveness and Health Policy (IECS) together with an
advisory committee overseeing the project, composed of 1
representative of a Ministry of Health, 1 academic member, 2
leaders of HTA agencies, and 1 member of a chamber of diagnostic
technology producers. A broader group of key stakeholder groups
was also convened to participate from academia, technology users,
patients, public and private healthcare decision makers, and HTA
specialists.
This study—carried on between February 2019 and February
2020—had 2 clearly defined stages, each with different method-
ological approaches: (1) targeted systematic review, with the aim
to identify current VFs and their dimensions; and (2) design of a
VF proposal through a mixed-methods, qualitative-quantitative
approach. We summarize in Table 1 the process and the different
stages involved. It was funded by an educational unrestricted
grant from Roche Diagnostics. The sponsor had no role in the
design, conduct, or reporting of the study. As all other participants
involved, they reviewed the materials and gave feedback. This
article is based on the work of the researchers, advisory com-
mittee, and stakeholders and on discussions held during the
project. It is not based on a formal consensus methodology and,
therefore, should not be interpreted as necessarily representative
of the views of the participants or the organizations in which they
work. The views expressed in this article are those of the authors
and do not necessarily reflect the position of any other involved in
the process.
First Stage: Targeted Systematic Literature Review and
Identification of the Components of the Value
Framework and Initial List Proposed
Targeted literature review
We did a scoping review of the literature to identify VFs tar-
geted to the evaluation of diagnostic tests or adaptations of
generic VFs for the evaluation of diagnostic tests. Inclusion criteria
were publications that described a VF (defined as a set of criteria
or attributes that assist in defining the global value of particular
health technologies) targeted to assist in the decision-making
process of diagnostic tests, published from January 2000 to
July 2019.
We searched MEDLINE, LILACs, and other generic sources
(Google Scholar, Google, Tripdatabase) with the following search
strategy in MEDLINE: (Value framework* [tiab] OR Assessment
Framework* [tiab]) AND Diagnos* [tiab]); the following terms
were searched in the rest of the databases: “Assessment
Table 1. Stages of the project.
Components Objectives Methods Tasks
First stage Literature review Identify VFs oriented to diagnostic
technologies
Identify criteria and subcriteria of VFs




Initial list of criteria Create a draft of VF Qualitative Researchers consensus meeting
Second stage Criteria categorization Categorize criteria and subcriteria,
hierarchically
Identify new criteria from stakeholders’
survey





Quantitative/Qualitative Face-to-face meeting (workshop)
with stakeholders
Exploratory research Identify barriers and facilitators of VF
implementation
Identify particular aspects of diagnostic
technology vs drug assessments
Quantitative/Qualitative
Final version of VF Generate a VF for diagnostic
technologies assessment
Quantitative/Qualitative Researchers consensus meeting
Synthesis of data, integration of
comments and
recommendations
VF indicates value framework.
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Table 2. Value frameworks identified.
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Framework 1 Diagnostic,” “Value Framework 1 Diagnostic.” We
additionally did manual and gray literature searches in the web-
pages of the main HTA agencies, academic institutions, public or
civil society organisms, health ministries, governments, and sci-
entific and patient societies, among others. The search was done in
English and Spanish.
We included all the articles and sites that described a VF for
diagnostic technologies regardless of who had been the de-
velopers (eg, agencies of HTA, scientific organizations, indepen-
dent researchers, producers’ chambers), their scope width within
diagnostic technologies (ie, if they were designed for a special
type of tests such as companion test or genetic test), their meth-
odology, or their funding. Finally, data from full-text articles of the
included VFs was extracted. Two independent researchers
participated in the selection process and screening titles and ab-
stracts; disagreement was resolved by consensus and an eventual
participation of a third researcher.
Identification of the components of the value
framework
Candidate criteria or dimensions to be considered in a VF were
identified and extracted from the literature review. In this article
we use interchangeably the words “criterion,” “dimension,” or
“domain”: a particular aspect or area that is considered when
assessing the value of a diagnostic technology that could be
considered to inform a decision. We define subcriteria (or sub-
domains or subdimensions) as different components “nested”
within a criterion or dimension in cases where a dimension in-
cludes several different aspects. An exhaustive set of criteria and
subcriteria was generated—in a free text form—in an Excel tem-
plate extracting the data of the literature review. One researcher
extracted the data while the others independently checked the
extracted templates for completeness and accuracy. An initial
comprehensive list with criteria and subcriteria was constructed.
Initial list of criteria proposed
Our research team worked on the initial list eliminating
redundant and consolidating overlapping criteria. A smaller
number of criteria and subcriteria from the list that were judged
to include all the key dimensions and subdimensions were kept.
This process was done in a deliberative way to arrive at a
consensus among our research team and the advisory committee
in order to keep an extensive but reasonable list of criteria and
subcriteria for a VF that is planned to be used in real-life settings.
Second Stage: Generation of the Proposed Value
Framework
This value framework was developed to be used for assessing
the value of any diagnostic technology as any technology or pro-
cedure that is used to confirm, exclude, or classify a health prob-
lem. It is intended to be used in the context of the decision making
specifically targeted to HTA agencies; Ministries of Health; and
other public or private healthcare payers and providers (ie, to
decide whether to incorporate a new diagnostic technology into a
coverage package, to disinvest in a diagnostic technology with
current coverage or in the acquisition of a diagnostic technology
by a health service provider). The number of criteria was not
predefined a priori in order to include all relevant criteria that our
heterogeneous stakholders’ group considered and to be as
comprehensive as possible.
Preliminary value framework proposed
The next step consisted of a first round of consultation with the
stakeholders. Through an online survey (performed in Survey-
Monkey), the initial list of selected criteria and subcriteria were
assessed. All participants judged the relevance of each criteria and
subcriteria and proposed new criteria they judged were important
in the value assessment of diagnostic technologies and were
Table 2. Continued
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omitted in our initial list. They categorized those criteria and
subcriteria according to an importance scale. Each respondent had
to indicate (on a scale of 0 to 10) how important the criteria or
subcriteria proposed was for them to be included in a value
framework targeted to diagnostic technology. Text labels were
also used to relate the 0 to 10 scale to importance adjectives (9-10,
essential or key; 7-8, high importance; 5-6, medium importance;
1-4, low importance; 0, not a candidate to be part of the VF).
A secondary objective of this survey was to find out the opinion of
the respondents about the distinctive characteristics of diagnostic
technologies—as opposed mainly to drugs—at the time of being
assessed through a generic value framework.
Finally, each criterion and subcriterion was assigned to a
relevance category (essential or key, high importance, medium
importance, low importance, and not a candidate to be part of the
VF) according to the most voted relevance category for each cri-
terion. After analyzing the results of the survey, we generated a
preliminary version of the proposed VF with the criteria and their
categorization.
Face-to-face validation of the preliminary VF and
exploratory qualitative research
This second round consisted of a full-day face-to-face work-
shop with the stakeholders, including the advisory committee.
The format of this meeting included presentations, small-group
dynamics, and plenary discussions. Small group activities con-
sisted in qualitative focus group discussions following a semi-
structured guideline. Focus group participants used the results of
the survey and had to validate or recommend changes to the
initial categorization of the criteria and subcriteria, and to provide
their opinion regarding the appropriateness of the new criteria or
subcriteria proposed during the survey (through an online survey
performed during the meeting to categorize new criteria or sub-
criteria). Through plenary sessions, they identified potential bar-
riers and facilitators for the application of VF, and they discussed
key messages to consider and the particular differences encoun-
tered when assessing these technologies compared to drugs. In
case of disagreement, consensus was reached through a deliber-
ative process. All the face-to-face activities were coordinated and
guided by the leading group of researchers.
Final version of the proposed value framework
The researchers’ group synthetized the data gathered in the
workshop using notes and online surveys performed. They pro-
duced a final list as well as their final categorization of criteria and
subcriteria (essential, high importance, medium importance, low
importance, or not considered relevant) of the proposed value
framework.
Results
First Stage: Targeted Systematic Literature Review and
Identification of the Components of the Value
Framework and Initial List Proposed
Targeted systematic review
A total of 73 citations were initially identified through MED-
LINE. Sixty-eight studies were discarded based on the titles and
abstracts owing to either not being a VF, or being a VF not targeted
to diagnostic technologies, so only 5 were retrieved from this
search stage; 15 were retrieved from other sources. This left a total
of 20 studies that met our inclusion criteria and were subse-
quently abstracted.5,7,23-40 The Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) flowchart is shown
in Figure 1.
All these studies were published in English from 2000 to 2019.
Seven VFs (or guidelines to use a preexistent generic value
framework in the context of diagnostic technologies) were
developed by HTA agencies, 5 by consultants commissioned by
industry associations of diagnostic technology or technology
producers, 4 reflected the work of independent researchers, and 4
were undertaken by academic or scientific associations. All the VFs
identified were developed in high-income countries; 5 of them
were from international organizations, 6 originated in European
countries, and 9 in North America and Australia. None were
generated in Latin American countries or other low- and middle-
income countries. In the majority of cases (85%), it was a VF
developed ad hoc for the evaluation of diagnostic tests; the rest
(15%) were guides adapting the use of a preexisting generic VF to
the evaluation of diagnostic technologies—for example, the Eu-
ropean Network for Health Technology Assessment (EUnetHTA)
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.
Title and abstract excluded n=60
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Table 3. Preliminary value framework and final value framework proposed (and ratings).
Criteria Preliminary value framework Value framework proposed

























75% 21% 4% 0% 0% U
Economic
Aspects
54% 38% 8% 0% 0% U
Severity of the
disease








25% 58% 17% 0% 0% U
Disease burden 42% 50% 8% 0% 0% U
Equity 25% 38% 38% 0% 0% :
Ethical and legal
aspects





27% 44% 22% 11% 0% U
Innovation 7% 41% 33% 7% 11% ;;
Nonclinical
benefits
4% 32% 60% 4% 0% U
Environmental
impact
19% 26% 37% 11% 7% U
Broader social
impact
4% 26% 41% 22% 7% U
Note. Those criteria that were suggested during the online survey by stakeholders are marked in bold. The gray background indicates the highest value reached in each category.



















Core Model or the National Institute for Health and Care Excel-
lence (NICE) Diagnostic Assessment Program. Of the included VFs,
11 were developed for some special test subtype (eg, companion
test, molecular diagnostic test, genetic test, tuberculosis-oriented
test), whereas only 9 were designed for any type of diagnostic
technology. There were 2 VFs specifically targeted to the tech-
nology reimbursement process, whereas the majority were ori-
ented to assist in the assessment of value of these technologies by
different stakeholders. Diagnostic VFs are identified and their key
characteristics summarized in Table 2. In Appendix 1 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2020.11.
008, a complementary and detailed description of their objec-
tives and components is also available.
Value framework criteria and subcriteria identification
We initially consolidated a unique list of criteria and sub-
criteria by eliminating duplicates and unifying overlapping ones.
Criteria such as effectiveness or accuracy were present in most
VFs, whereas equity, sustainability, ecologic impact, or ethical
aspects were the least frequent criteria in the diagnostic VFs
included.
Initial list of criteria proposed
An initial list consisting of 9 criteria and 21 subcriteria was
identified from the 20 studies that met our inclusion criteria,
along with their definitions. The criteria list is shown in Table 3
(preliminary value framework section), and their definitions and
Table 4. Value framework proposed.
Essential/core
Criteria* Subcriteria*
Clinical Benefit and Test Performance Clinical consecuences of the use of the test
Test performance
Safety and Unwanted consequences Procedural safety
Consequences of the wrong diagnosis
Safety of test preparation
Safety of test operators
Quality of scientific evidence
Economical aspects Economic evaluation (clinical effectiveness and/or
budget impact analysis)
Other costs
Organizational aspects and feasibility within the clinical path Impact on the health services provision system
Impact on the path of patient care
High importance
Health priority of the health system
Disease burden
Equity Neglected diseases test
Test in communicable diseases and high prevalence
Low access to health services
Ethical and legal aspect
Severity of the disease
Absence of alternative diagnostic technologies
Medium importance
Nonclinical benefits Experience of who takes the test
Value of the information
Load on caregivers or family
Preparation and/or care







*See definitions of criteria and subcriteria in Appendix 3 (in Supplemental Materials found at https://doi.org/10.1016/j.jval.2020.11.008).
-- 7
subcriteria are shown in Appendix 2 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2020.11.008.
Second Stage: Proposed Value Framework Generation
Preliminary value framework proposed
The survey was answered by all stakeholders (N = 31), and
criteria and subcriteria were classified according to their perceived
importance. None of them ranked as “low importance” or as a
candidate for exclusion. Equity had a tie in the number of re-
sponses of 2 neighboring categories, so it was left in this way with
the objective of solving that difference during the subsequent
face-to-face (workshop) validation stage. Six criteria not proposed
in the initial list were suggested during the survey: ethical and
legal aspects; absence of alternative diagnostic technologies;
severity of the disease; broader social impact; environmental
impact; and innovation. See Table 3 where this process is shown in
detail.
Face-to-face validation of the preliminary VF and
exploratory research
A total of 30 stakeholders, which represented a broad spec-
trum of the healthcare sector, attended the meeting held a month
after the survey. Five were representatives from governmental
offices, 5 public or private payors, 4 from HTA agencies, 8 from the
academia, 2 representatives of technology producers’ chambers, 4
technology producers, 2 representatives of a scientific society, and
1 representative of a patient advocacy program. All except 1 as-
sistant from the UK were from the Latin American region
(Argentina [14], Brazil [6], Colombia [2], Mexico [3], El Salvador
[1], Costa Rica [1], Perú [1]). Two plenary discussions and 2 small
group work phases were held. During the meeting, the 6 new
criteria proposed during the survey were categorized (using the
same hierarchical scale) through an instant voting system. The
results can be seen in bolded font in Table 3. Then during working
groups, a total set of 15 criteria and 21 subcriteria were analyzed
for the second validation round. As a result of this step, stake-
holders agreed that 11 of 15 criteria remained at the same cate-
gorization status during face-to-face validity round, whereas 4
were recategorized. (see Table 3). A list of barriers and facilitators
for the use of the VFs in diagnostic technologies were identified
and debated. These and the key messages for the diagnostic
technology assessment can be found in Tables 4 and 5.
Final version of value framework proposed
After the final integration and after stakeholder consultation
described above, 15 criteria and 21 subcriteria for defining the
value of a diagnostic technology were included. Five criteria were
rated as essential or core, 6 of them as highly relevant (high
importance), and 3 as moderately relevant (medium importance);
only 1 of them was judged as of low relevance (less importance).
Table 4 (and Appendix 3 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2020.11.008) show the different
criteria and subcriteria of this value framework targeted to the
assessment of broad diagnostic technologies. Some criteria were
recategorized during the workshop—for example, organizational
impact was reconsidered from being a high-importance criterion
to being an essential criterion, and equity was also recategorized
(from initially being of medium importance to high importance).
Innovation, which had been initially categorized as of medium
importance, was finally placed in the low importance category.
Discussion
Diagnostic technologies present particular challenges in value
assessment for decision makers.7,41 Several diagnostic VF exist, but
they are either outdated, not based on a systematic evidence
search and collaborative process, developed in only 1 jurisdiction,
aiming at only 1 type of diagnostic technology, or potentially
biased toward a particular perspective. Additionally, all were
produced in high-income contexts. Our project developed new
diagnostic technologies VF, based both on synthetizing the liter-
ature on existing VF and complementing this with a deliberative
and iterative process with a broad range of stakeholders related to
the HTA world in Latin America.
Frameworks identified came mostly from high-income coun-
tries where HTA and decision-making processes are more mature
for the need and use of a VF to complement the more established
assessment of drugs. In Latin America there is a lag in the use of
VFs in HTA, where they can be a valuable tool to promote greater
Table 5. Main barriers and facilitators for implementing diagnostic value frameworks and differential aspects in the assessment of
diagnostic technologies.
Barriers Facilitators
Underutilization of value frameworks in general,
not only in diagnostic technologies
Good reception of any effort aimed at improving HTA processes
Difficulty finding the evidence to support the
components of the framework
Industry, payers, and government aligned on the need for an
opportunity for dialogue between the parties
Lack of technical capacity in HTA processes Absence of a defined and legitimate framework that makes
coverage decisions transparent
Health systems are fragmented, and it is difficult
for everyone to incorporate the same framework
Opportunity window to standardize the evaluation processes
of health technologies
Differential aspects of diagnostic technologies compared to other technologies (mainly drugs)
Diagnostic technologies must always be considered in the context of the patient’s treatment path.
It is necessary to be precise to apply a common and homologated taxonomy in the evaluation of diagnostic technologies.
It is difficult in these technologies to translate the evidence into the decision.
The local clinical practice guidelines do not usually specify the type of diagnostic test necessary as if they do it with drugs.
In the context of value-based medicine, it is difficult to reflect the value of diagnostic technologies.
HTA indicates health technology assessment.
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transparency in the decision-making process and to facilitate the
participation of key stakeholders.42 Regarding the development of
VFs aimed for use in a broad spectrum of tests, they were made
mostly by HTA agencies and government offices to complement
the established process in place regarding drugs. More specific VF,
such as those for companion diagnostic tests and genetic tests,
were usually shaped by scientific societies, researchers, and
technology producers. Only a few were specifically targeted to-
ward the reimbursement process (Palmetto MolDX or the National
Framework for codependent technologies in Australia) and were
developed for specific kind of diagnostic tests, such as molecular
and companion tests.24,30
Some VFs share a common root—for example, with the ones
proposed by the Evaluation of Genomic Applications in Practice
and Prevention (EGAPP), Advisory Committee on Heritable Dis-
orders in Newborns and Children (ACHDNC), United Kingdom
Genetic Testing Network (UKGTN), and EuroGentest are based in
the ACCE model process for evaluation of genetic tests frame-
work.25,36,37,40 The ACCE framework takes its name from the 4
main criteria for evaluating a genetic test—analytic validity, clin-
ical validity, clinical utility, and associated ethical, legal, and social
implications—and is composed of a set of 44 questions.43
Our VF shares several dimensions with other VFs, such as
clinical validity, clinical utility, analytical validity, and economic
aspects, but also includes some other dimensions not usually
considered in other VFs (such as equity, innovation, the impact on
caregivers, safety to the personnel that performs the test, the
potential environmental impact, and technology sustainability).
We employed a mixed methodology to design the framework,
where qualitative methods were merged with a quantitative
approach. Another characteristic of our VF is that it also assessed
the importance of the difference criteria: from the 15 criteria, 5
were considered essential, 6 of high, 3 of moderate, and 1 of low
importance. Nevertheless, as relative importance of values can
vary in different settings, decision makers can customize this VF
and prioritize either the 5 essential criteria (or 11 if including
those of high importance) or choose their unique set in the
decision-making process and not use the whole VF.
We developed our framework aiming at the assessment pro-
cess of a wide range of diagnostic technologies, incorporating the
perspectives of multiple stakeholders. We consider that its main
use could be to inform the process of designing a benefit package
or the incorporation of these technologies in any health subsector.
The proposed VF builds on previous knowledge and reflects
current opinions and perspectives of the main actors of the health
system, from the technology producers to users, payers, patients,
and caregivers. Starting from the systematic targeted literature
review and an initial list of criteria, each of the participants had
the opportunity to assess them and propose additional di-
mensions they considered important, which were then also dis-
cussed and rated by the whole group. This open dialogue
generated a broad set of 15 criteria to consider when valuing these
technologies. We believe that one of the big assets of our VF is the
fact that it was led by an independent academic group through an
educational and unrestricted grant, as well as that the heteroge-
neous group of stakeholders had a predominance of HTA agency
officials and public and private payers, with the additional inclu-
sion of technology producers, regulators, patients, and academics.
Our aimwas also centered on capturing different perspectives and
being as comprehensive as possible but going further in the quest
to fill the gap in assessing the complexity of diagnostic tests. Due
to the methodology we followed (Latin American participants,
with more participation by HTA professionals from governments,
agencies, payers, and academia, and an equal weighting scheme in
the process), this VF reflects the inherent value structure of this
unique experience and is probably more oriented to governmental
and payer decision-making. Further research could explore its
extrapolation to other groups, regions, and settings.
Most countries lack a specific process regarding the assess-
ment of diagnostic technologies for their funding. At this partic-
ular moment, the world is facing several dilemmas, among which
is the uncertainty in decision making about diagnostic tests stra-
tegies for COVID-19 pandemic. Each jurisdiction has its own pe-
culiarities in health system, access to technology, equity, and even
geographical differences to consider while deciding which test to
incorporate into a comprehensive strategy against the virus.
Our VF could be useful for decision makers who currently do
not have a “fit for purpose” VF when assessing diagnostic tech-
nologies, and especially in lower- and middle-income countries,
focused on reimbursement and/or benefit package design.
Most of the participants agreed on the need for a VF that
makes decision making transparent and that facilitates the
evaluation of diagnostic tests within the entire patient care
process. Organizational challenges that these technologies imply,
access to diagnostic technologies but also to treatments result-
ing from the presence of a diagnosis, aspects of equity, and
impact of the environment were highlighted as differential
components that must be present when evaluating a diagnostic
technology.
A potential limitation of our VF for potential widespread use is
that, even considering that the targeted systematic review was
global, the stakeholder group was composed mainly of Latin
American actors. Future studies could assess its validity in other
contexts or countries.
The International Society for Pharmacoeconomics and Out-
comes Research Devices and Diagnostics Special Interest Group in
2016 reviewed 5 selected European and North American
diagnostic-specific HTA programs (specifically targeted to molec-
ular diagnostics) and their frameworks, aiming to identify com-
mon and best practices.9 They concluded that the HTA process and
posterior reimbursement decision should have transparent pro-
cesses and a stronger link between the HTA and funding decisions
and a recognition that these technologies require a differential
approach during it assessment. It exceeds the scoping of this work
to determine whether the effort to propose a specific VF will ul-
timately result in a better assessment of diagnostic technologies.
Nevertheless, any effort that assists in providing transparency and
accountability within the process of incorporation or rejection of a
diagnostic technology is valuable.
Our study provides an up-to-date, evidence- and stakeholder-
informed VF that includes 15 criteria and can be a useful tool to
specifically assess the value of diagnostic technologies. Future
steps for its implementation include criteria operationalization for
its use in real-life settings, assessing its usability and impact on
decision making in different settings, and its transferability to
other lower and middle income or high-income settings.
Supplemental Materials
Supplementary data associated with this article can be found in the
online version at https://doi.org/10.1016/j.jval.2020.11.008.
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